Next Generation Sequencing Based Tumor Profiling Test
Pathology · 21 CFR 866.6080
A next-generation sequencing based tumor profiling test is a qualitative in vitro diagnostic test intended to detect mutations in a broad panel of targeted genes that are somatically altered in malignant neoplasms from tumor specimens obtained from patients diagnosed with malignant solid neoplasms using targeted next-generation sequencing.
Recent MDR events
0 adverse event reports on file
No MDR events on file for this product code.
Event type breakdown
No data available.
Most-reported manufacturers
No data available.
Recalls
0 recall events for this product code
No recalls on file for this product code.
Registered firms
6 firms currently registered for this product code
510(k) clearances
8 clearances for this product code
- Datar Cancer Genetics Private LimitedMay 12, 2026
K260235 · CellDx-Tissue
- Tempus AI, Inc.Sep 19, 2025
K241868 · xR IVD
- Geneseeq Technology, Inc.Aug 29, 2025
K250003 · GENESEEQPRIME NGS Tumor Profiling Assay (FFPE) (GS6005)
- Act GenomicsDec 23, 2022
K210017 · ACTOnco, ACTOnco IVD
- Nyu Langone Medical CenterJul 14, 2021
K202304 · NYU Langone Genome PACT (Genome Profiling of Actionable Cancer Targets)
- Personal Genome DiagnosticsApr 24, 2020
K192063 · PGDx elio tissue complete
- Nanthealth, Inc.Nov 9, 2019
K190661 · Omics Core
- Memorial Sloan-Kettering Cancer CenterNov 15, 2017
DEN170058 · MSK-IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets):a Hybridization-Capture Based Next Generation Sequencing Assay